PMA device
Proclaim family of SCS IPGs
Abbott Medical · Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW, Class III) · First FDA decision Jul 21, 2017, newest Mar 5, 2021Chronic pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
11
Naming "Proclaim"
MAUDE reports
40,607
Brand "Proclaim", since 2015
PubMed studies
248
Mentioning "Proclaim"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Proclaim family of SCS IPGs
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- Proclaim family of SCS IPGsPMA supplement
P010032-S168 · Decided Mar 5, 2021 · 177 days after receipt · Normal 180 Day Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
- Proclaim family of SCS IPGsPMA supplement
P010032-S156 · Decided Jun 5, 2020 · 210 days after receipt · Normal 180 Day Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
- Proclaim family of SCS IPGsPMA supplement
P010032-S149 · Decided Sep 17, 2019 · 180 days after receipt · Normal 180 Day Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Proclaim", any status and sponsor, newest update first.
- Efficacy and Feasibility of BurstDR SCS in Painful Diabetic NeuropathyEnrolling by invitation
TriCity Research CenterNot on our public-company list
NCT07250828 · 20 participants (planned) · Start Dec 15, 2025 · Primary completion Jan 2027
Device: BurstDR Spinal Cord Stimulation · For: Painful Diabetic Neuropathy (PDN); Diabetic Neuropathy; Neuropathic Pain and 1 more
Sites: Grand Island, Nebraska
Nora VanegasAcademic, hospital or other
NCT03526991 · 10 participants · Start Aug 1, 2021 · Primary completion Feb 28, 2026
Device: Spinal Cord Stimulator (SCS) · For: Parkinson Disease
Sites: New York, New York; Houston, Texas
- Prospective Evaluation of Clinical and Radiographic Outcomes Following Total Talus Replacement (PROCLAIM)Enrolling by invitation
Restor3DNot on our public-company list
NCT06311331 · 50 participants (planned) · Start Nov 6, 2024 · Primary completion Nov 2031
Device: Total Talus Replacement (TTR) · For: Avascular Necrosis of the Talus; Talar Osteochondral Defect of Ankle; Talar Dysfunction
Sites: Charlotte, North Carolina
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Proclaim", and for the whole product code for context.
This brand
40,607 reports: 5,374 malfunction, 35,138 injury, 87 death
Whole product code LGW
301,867 reports: 79,174 malfunction, 220,939 injury, 1,642 death
Newest reports for this brand
St. Jude Medical - Neuromodulation (Puerto Rico, LLC)
3006705815-2026-06783 · Received Oct 30, 2026 · Event dated Aug 21, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Therapeutic or Diagnostic Output Failure
Patient problem as coded: Inadequate Pain Relief
St. Jude Medical - Neuromodulation (Puerto Rico, LLC)
3006705815-2026-06879 · Received Oct 30, 2026 · Event dated Oct 10, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
1627487-2026-10964 · Received Oct 30, 2026 · Event dated Oct 7, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Implant Pain
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Eterna SCS IPG (Implantable Pulse Generator), Model Number 32400Open, Classified
Z-0458-2026 · Started Oct 6, 2025 · Posted by FDA Nov 7, 2025
Reason given: There is a potential issue affecting Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generators (IPGs), Model 32400 and Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generators (IPGs), Model 62400 . These devicess may experience a loss of communication with the Clinician Programmer (CP) and/or the...
Cause as FDA categorized it: Process control · Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Z-2505-2023 · Started Jul 18, 2023 · Posted by FDA Sep 11, 2023
Reason given: Firm has received complaints from patients who are unable to exit MRI (Magnetic Resonance Imaging) mode on their IPGs (Implantable Pulse Generators).
Cause as FDA categorized it: Under Investigation by firm · Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Z-2506-2023 · Started Jul 18, 2023 · Posted by FDA Sep 11, 2023
Reason given: Firm has received complaints from patients who are unable to exit MRI (Magnetic Resonance Imaging) mode on their IPGs (Implantable Pulse Generators).
Cause as FDA categorized it: Under Investigation by firm · Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
11 more recall records with a free account
Published research
The most relevant PubMed records for "Proclaim"[tiab]. The summary above synthesizes these.
- Abortion.
Johnson B · Br Med J · 1979Letter
- When dissident bodies proclaim their places as dissonant bodies.
Moreira R, Santos MLMD, Rosa NSF, et al. · Cien Saude Colet · 2024
- On a Corresponsive Sport Science.
Woods CT, Araújo D, Davids K · Sports Med · 2024
- Proclaimࡊ DRG Neurostimulator System for the management of chronic, intractable pain.
Hagedorn JM, Demian PS, Scarfo KA, et al. · Pain Manag · 2020
- PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Senan S, Brade A, Wang LH, et al. · J Clin Oncol · 2016Clinical Trial, Phase III, Randomized Controlled Trial
- Measles eradication-retreating is not an option.
Durrheim DN · Lancet Infect Dis · 2020Review
- The ethics of dysfunctional professional relationships.
Jones JW, McCullough LB · J Vasc Surg · 2016Editorial
- Toxic evaluation of Proclaim Fit® on adult and larval worker honey bees.
Ghasemi V, Salehinejad A, Ghadamyari M, et al. · Ecotoxicology · 2022
- The great intimidators.
Kramer RM · Harv Bus Rev · 2006
- PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology.
Vokes EE, Senan S, Treat JA, et al. · Clin Lung Cancer · 2009Clinical Trial, Phase III, Comparative Study
- Device profile of the Proclaim XR neurostimulation system for the treatment of chronic pain: an overview of its safety and efficacy.
Hagedorn JM, Engle AM, Ghosh P, et al. · Expert Rev Med Devices · 2020Review
- PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.
Willerson JT, Cable G, Yeh ET · Tex Heart Inst J · 2009Clinical Trial, Phase IV, Multicenter Study
Other devices of this type
Also filed under product code LGW.
- Precision Spinal Cord Stimulator (SCS) SystemsBoston Scientific Corp · PMA 2026
- Senza Spinal Cord Stimulation (SCS) SystemNevro Corporation · PMA 2025
- Saluda Medical Evoke SCS SystemSaluda Medical Pty, Ltd. · PMA 2026
- Master RestoreMedtronic Neuromodulation · PMA 2026
- RestoreMedtronic Neuromodulation · PMA 2025
- Genesis and Eon Family Neurostimulation (Ipg) SystemsAbbott Medical · PMA 2016
- Genesis Neurostimulation SystemAbbott Medical · PMA 2024
- Precision Spectra Spinal Cord Stimulator (SCS) SystemBoston Scientific Corp · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.